At what enterprise value was SEBIA acquired in 2025?

During the acquisition of SEBIA by WARBURG PINCUS in 2025, the company was valued at an estimated revenue multiple of 10x - 18x. The transaction's Enterprise Value is estimated to be in the range of 3b - 100b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of SEBIA when it was acquired by WARBURG PINCUS?

The estimated EV/EBITDA multiple for SEBIA is in the range of Above 20x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.4x. Join our community for free to access full valuation data and industry trends.

When was SEBIA acquired by WARBURG PINCUS?

SEBIA was acquired by WARBURG PINCUS in 2025.

What was the revenue of SEBIA at the time of the deal?

The revenue of SEBIA at the time of the deal is estimated to be in the range of 450M - 900M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of SEBIA during the acquisition?

SEBIA's EBITDA is estimated to be in the range of 150M - 250M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the SEBIA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the SEBIA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/sebia-se-valorise-plus-de-5-mdeur-aupres-de-warburg-pincus-2192808

← DATABASE

Home Database Healthcare & PharmaSEBIA

08/2025

SEBIA acquired by WARBURG PINCUS

FRANCE Life Sciences / Medical Devices / Diagnostic Equipment EV 3b - 100b EUR

Context

The French medical diagnostics giant Sebia welcomes a new heavyweight investor, Warburg Pincus, into its capital. This transaction, valuing the company at over EUR5 billion, sees the partial exit of minority shareholders CDPQ and ICG. The current majority owners, CVC Capital Partners and Tethys Invest (the Bettencourt-Meyers family office), retain a significant stake and will continue to back the company alongside Warburg Pincus. This new consortium aims to support Sebia's expansion in the US and Asian markets and fund potential acquisitions in the IVD space.

Historically, the company has already experienced a leveraged buyout orchestrated by Cvc in 2017.

SEBIA, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

A global leader in in-vitro diagnostics (IVD), specializing in clinical electrophoresis technology. Founded in 1967, Sebia provides automated equipment and reagents used by medical laboratories worldwide to screen and monitor diseases such as multiple myeloma, metabolic disorders (diabetes), and hemoglobinopathies. The company generates over 90% of its sales internationally and has a direct presence in 15 countries.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Other operations with SEBIA

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
10/2017	CVC	SEBIA	FRANCE	Life Sciences	CVC and the Canadian company CDPQ are acquiring control of the medical diagnostics specialist Sebia. The company is valued at nearly EUR2 billion, according to multiple sources.

REFERENCES

Valuation range: EV 3b - 100b EUR

Revenue range: 450M - 900M EUR

EBITDA range: 150M - 250M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SEBIA by WARBURG PINCUS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: sebia

Acquirer: warburg pincus